Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of 20(S)-ginsenoside Rg3 in preparation of medicines for treating non-small cell lung cancer

A technology of non-small cell lung cancer and ginsenoside, which is applied in the field of drug research and can solve the problems of non-small cell lung cancer with no drugs found

Inactive Publication Date: 2011-10-12
北京鑫利恒医药科技发展有限公司
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, no drug has been found to be effective in the treatment of non-small cell lung cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of 20(S)-ginsenoside Rg3 in preparation of medicines for treating non-small cell lung cancer
  • Application of 20(S)-ginsenoside Rg3 in preparation of medicines for treating non-small cell lung cancer
  • Application of 20(S)-ginsenoside Rg3 in preparation of medicines for treating non-small cell lung cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] This example relates to the study of 20(S)-ginsenoside Rg3 inhibiting the growth of non-small cell lung cancer. 1. Experimental materials and methods

[0044] (1) Main materials

[0045] 1. Experimental animals: BALB / C-nu nude mice, female, 4-6 weeks old, weighing 18-22 grams. They were purchased from the Institute of Experimental Animals, Chinese Academy of Medical Sciences and Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. respectively. Certificate number: SCXK (Beijing) 205-0013 and 2007-0001. The experiments and feeding were carried out in the ultra-clean laminar flow frame under SPF conditions. The sterilized water and feed were provided to the animals for free intake, and all operations were carried out in a sterile ultra-clean workbench.

[0046] 2. Selected tumor line: NCI-H460 human large cell lung cancer cell line, purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences. A549 human lung adenocarcinoma was donated by the Inst...

Embodiment 2

[0100] This example relates to the effect of SPG-Rg3 on the expression of CD34 in non-small cell lung cancer tissue and the expression of apoptosis genes in non-small cell lung cancer cells

[0101] 1. Experimental materials and experimental methods

[0102] 1. Main reagents: CD34 monoclonal antibody and SP kit (both purchased from Fuzhou Maixin); TUNEL apoptosis kit (Roche)

[0103] 2. Experimental equipment: FV500 laser confocal microscope (OLYMPUS); paraffin microtome (Germany LEICA, RM 2245); immunohistochemical staining incubation box, microscope (OLYMPUS BX51, Japan).

[0104] 3. Immunohistochemical staining method: the tumor tissues (H460 large cell lung cancer and A549 lung adenocarcinoma) of the blank control group and the SPG-Rg3 (1.0mg / kg) treatment group were fixed in 10% neutral buffered formaldehyde for 24 hours, Paraffin embedding, serial sectioning (4 μm), and CD34 staining were performed using the SP method, step by step according to the kit instructions. Th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to medicine application of 20(S)-ginsenoside Rg3, in particular to application of 20(S)-ginsenoside Rg3 in preparation of medicines for treating a non-small cell lung cancer. In the invention, selecting a human non-small cell lung cancer cell strain (A549 lung adenocarcinoma, H460 large cell lung cancer and LTEP-78 lung squamous carcinoma) to be inoculated under the skin of a naked mouse, and observing the influence of the SPG-Rg3 on the non-small cell lung cancer; and carrying out CD34 immunohistochemistry staining and TUNEL immunofluorescence staining on tumor tissues,and observing the influence of the SPG-Rg3 on tumor angiogenesis and apoptosis. The inclusion proves that the 20(S)-ginsenoside Rg3 can remarkably inhibit the growth of the non-small cell lung cancer, has the action mechanism related with the promotion of the tumor apoptosis and the inhibition of the tumor angiogenesis and unobvious cooperation action when being combined with cyclophosphamide forapplication, and can be used for the clinical chemotherapy of the non-small cell lung cancer.

Description

technical field [0001] The invention belongs to the field of drug research, and specifically relates to the application of 20(S)-ginsenoside Rg3 as a medicine for treating non-small cell lung cancer. Background technique [0002] Lung cancer is a common clinical malignant tumor, which is usually divided into two categories: small cell lung cancer and non-small cell lung cancer. Accounting for the vast majority, the most common, accounting for more than 80% of the total number of lung cancer. The incidence of non-small cell lung cancer is increasing year by year all over the world, which seriously threatens human health. The current treatment methods for NSCLC mainly include the following: [0003] (1) Surgical treatment of NSCLC [0004] At present, the most ideal method for the treatment of NSCLC is still surgical treatment. The purpose of surgical treatment is to remove the lung cancer lesion and regional lymph nodes, and to preserve as much healthy lung tissue as poss...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/704A61P35/00
Inventor 赵文杰倪劲松李平亚
Owner 北京鑫利恒医药科技发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com